Key result
The Alere i Influenza A & B assay demonstrated sensitivities of 55.2-100% and specificities of 62.5-100% for Flu A, and 45.2-100% and 53.6-100% for Flu B across previously published evaluations.
Why the study?
Does the Alere i Influenza A & B assay accurately detect and differentiate influenza A and B?
Does the Alere i Influenza A & B assay accurately detect and differentiate influenza A and B?
The Alere i Influenza A & B assay provides a rapid, CLIA-waived molecular point-of-care test for influenza detection, though diagnostic accuracy varies across evaluations.
Answers are grounded in this paper and cite their sources.
May enable point-of-care molecular influenza testing; leaves open real-world accuracy versus reference standards.
INTRODUCTION: The Alere i Influenza A & B assay incorporates the Nicking Enzyme Amplification Reaction technique on the Alere i instrument to detect and differentiate influenza virus (Flu) A and B nucleic acids in specific specimens. Areas covered: The Alere i Influenza A & B assay was cleared by the US Food and Drug Administration for use with nasal swabs (NS) and nasopharyngeal swabs, either directly or in viral transport medium. Notably, direct use on NS was the first ever CLIA-waived nucleic acid-based test. Previously published evaluations have reported sensitivities and specificities of 55.2-100% and 62.5-100% for Flu A and 45.2-100% and 53.6-100% for Flu B, respectively. Expert commentary: The Alere i Influenza A & B assay provides a rapid and simple platform for detection and differentiation of Flu A and B. Efforts are expected to further improve sensitivity and user-friendliness for effective and widespread use in the true point-of-care setting.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2018) conducted a review in Influenza A & B. Alere i Influenza A & B assay was evaluated on Sensitivity and specificity for Flu A and Flu B. The Alere i Influenza A & B assay demonstrated sensitivities of 55.2-100% and specificities of 62.5-100% for Flu A, and 45.2-100% and 53.6-100% for Flu B across previously published evaluations.
Synapse has enriched 10 related papers. Consider them for comparative context: